Open house Arzneimittelrabattverträge Lacosamid (ausgenommen Darreichungsform Filmtabletten), ATC N03AX18
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lacosamid (ausgenommen Darreichungsform Filmtabletten), ATC N03AX18
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
The open-house model is explicitly stated as not subject to procurement law. This may reduce legal recourse options.
Existing or future public discount contracts for Lacosamide can automatically supersede these agreements.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Strong opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Sep 2026
- Provision of Lacosamide (excluding film tablet form) under non-exclusive discount agreements with AOK Bayern.
- Contracts are open to all interested pharmaceutical companies that meet eligibility.
Show full summary
AOK Bayern offers non-exclusive discount agreements (open-house model) for the active substance Lacosamide (excluding film tablets, ATC N03AX18). Any pharmaceutical company that meets the eligibility criteria can sign an identical, non-negotiable contract. Contracts run from 01.10.2024 to 30.09.2026, with enrollment possible until 05.08.2026. This is not a standard procurement procedure but a voluntary open-house model under German social law.
Risks
The open-house model is explicitly stated as not subject to procurement law. This may reduce legal recourse options.
Existing or future public discount contracts for Lacosamide can automatically supersede these agreements.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible as potential contract partners.
Administrative
- Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
- Submission of the signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.
Requirements may be incomplete.
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Lacosamid (ausgenommen Darreichungsform Filmtabletten), ATC N03AX18
Non-exclusive discount agreements for Lacosamide (excluding film tablets) with AOK Bayern. All eligible pharmaceutical companies can join on identical terms. Contracts are subject to automatic termination if a standard public discount contract for the same active substance comes into effect.
Location
Duration
Category
Deadline
Award details
Selection criteria
Show original TED data
Original TED description
Siehe kurze Beschreibung
Procurement Details
- Publication date
- 15 Aug 2024
- Notice type
- Contract notice — standard
- Languages
- German
Reference metadata
- Notice subtype
- 16
- Notice version
- 1
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 492583-2024
Documents (2)
Similar tenders
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Ganirelix (ATC-Code: H01CC01).
Czechia – Pharmaceutical products – Léčivý přípravek ATC skupiny R03DX05 s účinnou látkou OMALIZUMAB
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V über Arzneimittel mit dem Wirkstoff Denosumab Xgeva (ATC-Code nach WHO: M05BX04)
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Formoterol und Beclometason, ausgenommen Dosieraerosole mit der Wirkstärke 100µg/6µg (ATC-Code: R03AK08).
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Moldova – Pharmaceutical products – Achiziționarea centralizată a Reagenților pentru Investigații Clinice, Hematologice și PATOLOGICE conform necesităților IMSP - beneficiari pentru anul 2027
Opportunity Score
Why this score?
Opportunity
60 / 100
Complexity
20 / 100
Risk factors
The open-house model is explicitly stated as not subject to procurement law. This may reduce legal recourse options.
Existing or future public discount contracts for Lacosamide can automatically supersede these agreements.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications